Literature DB >> 17891257

Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine.

Ana Paula Werneck de Castro1, Helio Elkis.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the rehospitalization rates of patients discharged from the Institute of Psychiatry of the Hospital das Clínicas of the Universidade de São Paulo Medical School while being treated with haloperidol, risperidone or clozapine.
METHOD: This is a naturalistic study designed to monitor rehospitalization rates for patients discharged on haloperidol (n=43), risperidone (n=22) or clozapine (n=31). Time to readmission over the course of three years was measured by the product-limit (Kaplan-Meier) method. Risk factors associated with rehospitalizations were examined.
RESULTS: At 36 months, remained in the community 74% of the haloperidol-treated patients, 59% of the risperidone-treated patients and 84% of the clozapine-treated patients. The haloperidol group showed a higher proportion of women, a late age of onset and shorter length of illness than the other groups, whereas the opposite was observed in the clozapine group.
CONCLUSIONS: This study suggests that the rehospitalization rates of patients taking clozapine are lower than the rate for patients treated with haloperidol and risperidone. However confounding variables such as gender distribution and age of onset represent limitations that should be taken into account for the interpretation of the results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891257     DOI: 10.1590/s1516-44462007000300004

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  7 in total

1.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

2.  Genetic variability testing of neurodevelopmental genes in schizophrenic patients.

Authors:  Tea Terzić; Matej Kastelic; Vita Dolžan; Blanka Kores Plesničar
Journal:  J Mol Neurosci       Date:  2014-12-23       Impact factor: 3.444

3.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★.

Authors:  Junchao Huang; Yu Zhu; Fengmei Fan; Song Chen; Yuan Hong; Yimin Cui; Xingguang Luo; Shuping Tan; Zhiren Wang; Lan Shang; Ying Yuan; Jianxin Zhang; Fude Yang; Chiang-Shan R Li; Laura M Rowland; Peter Kochunov; Fengyu Zhang; L Elliot Hong; Yunlong Tan
Journal:  Psychiatry Res Neuroimaging       Date:  2020-02-04       Impact factor: 2.376

4.  Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia.

Authors:  Tea Terzić; Matej Kastelic; Vita Dolžan; Blanka Kores Plesničar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-20       Impact factor: 2.570

5.  Rate and Predictors of 1-year Readmission in Tertiary Psychiatric Hospitals.

Authors:  Afaf Ibrahim Al-Shehhi; Hamed Nasser Al-Sinawi; Sachin Jose; Randa Youssef
Journal:  Saudi J Med Med Sci       Date:  2017-08-21

6.  Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine.

Authors:  Jad Kesserwani; Giouliana Kadra; Johnny Downs; Hitesh Shetty; James H MacCabe; David Taylor; Robert Stewart; Chin-Kuo Chang; Richard D Hayes
Journal:  J Psychopharmacol       Date:  2019-01-08       Impact factor: 4.153

7.  The frequency of rehospitalization and associated factors in Colombian psychiatric patients: a cohort study.

Authors:  Luis Eduardo Jaramillo-Gonzalez; Ricardo Sanchez-Pedraza; Maria Isabel Herazo
Journal:  BMC Psychiatry       Date:  2014-06-02       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.